PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28427213-4	2017	The impact of continued crizotinib therapy on the patients" PFS2 time was assessed after adjusting for potential confounding factors.	Crizotinib	24-34	GINS complex subunit 2	Homo sapiens	60-64	
28427213-6	2017	With continued crizotinib therapy after documentation of PD, the median PFS2 for all 33 patients was 16 weeks, and in those with CNS progression but systemic disease control it was 30 weeks.	Crizotinib	15-25	GINS complex subunit 2	Homo sapiens	72-76	
28427213-8	2017	Multivariable Cox regression analysis showed that the PFS1 with initial crizotinib treatment and local therapy were independent predictors of PFS2.	Crizotinib	72-82	GINS complex subunit 2	Homo sapiens	142-146